Señales en vivo de MOLN.SW | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 11:30):

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins...

Stats
Volumen de hoy	43 540.00
Volumen promedio	12 418.00
Capitalización de mercado	111.75M
EPS	CHF0 ( 2024-03-15 )
Last Dividend	CHF0 ( N/A )
Next Dividend	CHF0 ( N/A )
P/E	-1.800
ATR14	CHF0.0290 (0.86%)

Molecular Partners AG Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Molecular Partners AG Finanzas

Annual	2023
Ingresos:	CHF7.04M
Beneficio Bruto:	CHF-40.81M (-579.80 %)
EPS:	CHF-1.890

FY	2023
Ingresos:	CHF7.04M
Beneficio Bruto:	CHF-40.81M (-579.80 %)
EPS:	CHF-1.890

FY	2022
Ingresos:	CHF189.56M
Beneficio Bruto:	CHF138.81M (73.23 %)
EPS:	CHF3.63

FY	2021
Ingresos:	CHF9.33M
Beneficio Bruto:	CHF0.00 (0.00 %)
EPS:	CHF-2.98

Financial Reports:

No articles found.

Molecular Partners AG

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.